{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T06:27:53Z","timestamp":1786343273561,"version":"build-2736575974"},"reference-count":37,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Intranasal corticosteroids (INCS) are first-line therapy for allergic rhinitis (AR), but their long-term skeletal safety in post-menopausal women\u2014who are inherently vulnerable to bone loss\u2014remains inadequately studied despite low systemic bioavailability.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      This retrospective cohort study included 691 post-menopausal women with persistent AR treated from 2015 to 2023. Participants were categorized into INCS (\n                      <jats:italic>n<\/jats:italic>\n                      = 198), second-generation antihistamine (sgAH,\n                      <jats:italic>n<\/jats:italic>\n                      = 187), combination therapy (\n                      <jats:italic>n<\/jats:italic>\n                      = 156), and control (\n                      <jats:italic>n<\/jats:italic>\n                      = 150) groups. Primary outcomes were changes in bone mineral density (BMD)\n                      <jats:italic>T<\/jats:italic>\n                      -scores and incident osteoporosis. Secondary outcomes included fragility fractures. Multivariable regression analyses were performed with adjustment for confounders, and dose-response relationships were evaluated using defined daily doses.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Over a median follow-up of 4.2 years, INCS users exhibited significantly greater declines in lumbar spine\n                      <jats:italic>T<\/jats:italic>\n                      -scores compared to controls, with similar findings at the femoral neck. sgAH users showed no significant bone loss. Dose-response analysis revealed linear trends for greater bone loss with higher cumulative INCS exposure. Incident osteoporosis occurred in 24.2% of INCS users vs. 11.3% of controls. Fragility fracture rates were highest in the INCS group with adjusted HR 3.85 (95% CI = 1.45\u201310.24,\n                      <jats:italic>p<\/jats:italic>\n                      = 0.007) vs. controls. sgAH showed no increased fracture risk (HR 1.13, 95% CI = 0.33\u20133.89). Subgroup analyses identified heightened risk in women aged \u226565 years and those with BMI &amp;lt; 23 kg\/m\n                      <jats:sup>2<\/jats:sup>\n                      .\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Long-term INCS use in post-menopausal women was associated with accelerated bone loss, increased osteoporosis risk, and higher fracture rates in a dose-dependent manner. These findings raise concerns regarding the assumption of complete INCS skeletal safety in post-menopausal women and suggest the need for enhanced bone monitoring in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1838641","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T05:30:32Z","timestamp":1786339832000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Long-term intranasal corticosteroids vs. antihistamines and bone health in post-menopausal women with allergic rhinitis: a retrospective cohort study"],"prefix":"10.3389","volume":"13","author":[{"given":"Xiaofei","family":"Jia","sequence":"first","affiliation":[{"name":"Department of Otolaryngology, The Second Hospital of HeBei Medical University","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lei","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Joint Surgery, The Third Hospital of Hebei Medical University, Shijiazhuang","place":["Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanzhong","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Otolaryngology, The Second Hospital of HeBei Medical University","place":["Shijiazhuang, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"874114","DOI":"10.3389\/fmed.2022.874114","article-title":"Allergic rhinitis: a clinical and pathophysiological overview","volume":"9","author":"Nur Husna","year":"2022","journal-title":"Front Med (Lausanne)."},{"key":"B2","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1186\/s13223-015-0101-1","article-title":"The gender, age and risk factor distribution differs in self-reported allergic and non-allergic rhinitis: a cross-sectional population-based study","volume":"11","author":"Cazzoletti","year":"2015","journal-title":"Allergy Asthma Clin Immunol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jaci.2019.06.049","article-title":"Next-generation allergic rhinitis and its impact on asthma (aria) guidelines for allergic rhinitis based on grading of recommendations assessment, development and evaluation (GRADE) and real-world evidence","volume":"145","author":"Bousquet","year":"2020","journal-title":"J Allergy Clin Immunol."},{"key":"B4","doi-asserted-by":"publisher","first-page":"3404","DOI":"10.1016\/j.jaip.2024.09.001","article-title":"Intranasal versus oral treatments for allergic rhinitis: a systematic review with meta-analysis","volume":"12","author":"Torres","year":"2024","journal-title":"J Allergy Clin Immunol Pract."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1184552","DOI":"10.3389\/fphar.2023.1184552","article-title":"Comparative efficacy and acceptability of licensed dose intranasal corticosteroids for moderate-to-severe allergic rhinitis: a systematic review and network meta-analysis","volume":"14","author":"Soe","year":"2023","journal-title":"Front Pharmacol."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.2147\/JAA.S321332","article-title":"Intranasal corticosteroids: topical potency, systemic activity and therapeutic index","author":"Daley-Yates","year":"2021","journal-title":"J Asthma Allergy"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3390\/children11080951","article-title":"Systemic adverse events associated with locally administered corticosteroids","author":"De Vleeschhauwer","year":"2024","journal-title":"Children"},{"key":"B8","doi-asserted-by":"publisher","first-page":"e062677","DOI":"10.1136\/bmjopen-2022-062677","article-title":"Moxibustion as adjuvant therapy for preventing bone loss in postmenopausal women: protocol for a randomised controlled trial","volume":"12","author":"Lu","year":"2022","journal-title":"BMJ Open."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1376","DOI":"10.3390\/ijms23031376","article-title":"Osteoporosis due to hormone imbalance: an overview of the effects of estrogen deficiency and glucocorticoid overuse on bone turnover","volume":"23","author":"Cheng","year":"2022","journal-title":"Int J Mol Sci."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1038\/nm1096-1132","article-title":"Estrogen promotes apoptosis of murine osteoclasts mediated by TGF-\u03b2","volume":"2","author":"Hughes DE Dai","year":"1996","journal-title":"Nat Med."},{"key":"B11","doi-asserted-by":"publisher","first-page":"177","DOI":"10.2147\/OARRR.S282606","article-title":"Understanding and managing corticosteroid-induced osteoporosis","volume":"13","author":"Kobza","year":"2021","journal-title":"Open Access Rheumatol."},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2021.106374","article-title":"Corticosteroids and bone health in people with asthma: a systematic review and meta-analysis","author":"Chalitsios","year":"2021","journal-title":"Resp Med"},{"key":"B13","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1007\/s11657-023-01246-6","article-title":"Prevalence of glucocorticoid-induced osteoporosis among rheumatology patients in Africa: a systematic review and meta-analysis","volume":"18","author":"Hmamouchi","year":"2023","journal-title":"Arch Osteoporos"},{"key":"B14","doi-asserted-by":"publisher","first-page":"964","DOI":"10.1016\/S2213-8587(25)00251-7","article-title":"Glucocorticoid-induced osteoporosis: novel concepts and clinical implications","volume":"13","author":"Hofbauer","year":"2025","journal-title":"Lancet Diabetes Endo"},{"key":"B15","doi-asserted-by":"publisher","first-page":"45","DOI":"10.12932\/AP-191019-0663","article-title":"Effect of inhaled corticosteroids on bone mineral density in patients with asthma","volume":"41","author":"Watanabe","year":"2023","journal-title":"Asian Pac J Allergy"},{"key":"B16","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1056\/NEJMoa002304","article-title":"Effects of inhaled glucocorticoids on bone density in premenopausal women","volume":"345","author":"Israel","year":"2001","journal-title":"N Engl J Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"e008554","DOI":"10.1136\/bmjopen-2015-008554","article-title":"Bone mineral density and fracture risk with long-term use of inhaled corticosteroids in patients with asthma: systematic review and meta-analysis","volume":"5","author":"Loke","year":"2015","journal-title":"BMJ Open."},{"key":"B18","doi-asserted-by":"publisher","first-page":"782","DOI":"10.1359\/jbmr.2001.16.4.782","article-title":"Inhaled corticosteroids reduce bone mineral density in early postmenopausal but not premenopausal asthmatic women","volume":"16","author":"Fujita","year":"2001","journal-title":"J Bone Miner Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"599","DOI":"10.2217\/WHE.14.40","article-title":"Nutrition and bone health in women after the menopause","volume":"10","author":"Rizzoli","year":"2014","journal-title":"Womens Health (Lond)."},{"key":"B20","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1007\/s11657-018-0537-2","article-title":"Long-term effects of inhaled corticosteroids on bone mineral density in older women with asthma or COPD: a registry-based cohort study","volume":"13","author":"Chen","year":"2018","journal-title":"Arch Osteoporos."},{"key":"B21","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1038\/s41598-020-80815-y","article-title":"Evaluating the association of osteoporosis with inhaled corticosteroid use in chronic obstructive pulmonary disease in Taiwan","volume":"11","author":"Chiu","year":"2021","journal-title":"Sci Rep."},{"key":"B22","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1370\/afm.240030","article-title":"Adverse outcomes associated with inhaled corticosteroid use in individuals with chronic obstructive pulmonary disease","volume":"23","author":"Pace","year":"2025","journal-title":"Ann Fam Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"1399","DOI":"10.1016\/S0140-6736(00)02138-3","article-title":"Inhaled corticosteroid use and bone-mineral density in patients with asthma","volume":"355","author":"Wong","year":"2000","journal-title":"Lancet."},{"key":"B24","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1016\/j.cytogfr.2023.03.002","article-title":"Pathogenic mechanisms of glucocorticoid-induced osteoporosis","volume":"70","author":"Chen","year":"2023","journal-title":"Cytokine Growth Factor Rev."},{"key":"B25","doi-asserted-by":"publisher","first-page":"E47","DOI":"10.1503\/cmaj.201266","article-title":"Using intranasal corticosteroids","volume":"193","author":"Fowler","year":"2021","journal-title":"Can Med Assoc J"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1143835","DOI":"10.3389\/fendo.2023.1143835","article-title":"Age-related modifications in CYP-dependent drug metabolism: role of stress","volume":"14","author":"Konstandi","year":"2023","journal-title":"Front Endocrinol (Lausanne)."},{"key":"B27","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/s40262-024-01466-0","article-title":"Influence of ageing on the pharmacodynamics and pharmacokinetics of chronically administered medicines in geriatric patients: a review","volume":"64","author":"Ngcobo","year":"2025","journal-title":"Clin Pharmacokinet."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e175089","DOI":"10.1172\/jci.insight.175089","article-title":"Protein kinase G2 activation restores Wnt signaling and bone mass in glucocorticoid-induced osteoporosis in mice","volume":"9","author":"Pal China","year":"2024","journal-title":"JCI Insight."},{"key":"B29","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1007\/s12020-011-9580-0","article-title":"Glucocorticoid-induced osteonecrosis","volume":"41","author":"Weinstein","year":"2012","journal-title":"Endocrine."},{"key":"B30","article-title":"An overview of glucocorticoid-induced osteoporosis","volume-title":"Endotext.","author":"Ilias","year":"2022"},{"key":"B31","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1007\/s00198-018-4564-z","article-title":"Antihistamine use and the risk of injurious falls or fracture in elderly patients: a systematic review and meta-analysis","volume":"29","author":"Cho","year":"2018","journal-title":"Osteoporos Int."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1111\/jgs.18372","article-title":"American Geriatrics Society 2023 updated AGS Beers Criteria\u00ae for potentially inappropriate medication use in older adults","volume":"71","author":"American","year":"2023","journal-title":"J Am Geriatr Soc"},{"key":"B33","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.bone.2013.08.013","article-title":"Proton pump inhibitor use and fracture risk-effect modification by histamine H1 receptor blockade. Observational case-control study using national prescription data","volume":"57","author":"Abrahamsen","year":"2013","journal-title":"Bone"},{"key":"B34","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s12020-022-03208-3","article-title":"Vitamin D in the older population: a consensus statement","volume":"79","author":"Giustina","year":"2023","journal-title":"Endocrine."},{"key":"B35","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1093\/ejendo\/lvae146","article-title":"Prevention and treatment of glucocorticoid-induced osteoporosis in adults: recommendations from the European calcified tissue society","volume":"191","author":"Paccou","year":"2024","journal-title":"Eur J Endocrinol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1186\/s13018-023-03920-4","article-title":"Clinical efficacy of denosumab, teriparatide, and oral bisphosphonates in the prevention of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis","volume":"18","author":"Yuan","year":"2023","journal-title":"J Orthop Surg Res"},{"key":"B37","doi-asserted-by":"publisher","first-page":"961","DOI":"10.7326\/0003-4819-125-12-199612150-00004","article-title":"Calcium and vitamin D3 supplementation prevents bone loss in the spine secondary to low-dose corticosteroids in patients with rheumatoid arthritis. A randomized, double-blind, placebo-controlled trial","volume":"125","author":"Buckley","year":"1996","journal-title":"Ann Intern Med."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1838641\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T05:30:33Z","timestamp":1786339833000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1838641\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":37,"alternative-id":["10.3389\/fmed.2026.1838641"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1838641","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]},"article-number":"1838641"}}